Open AccessPotential for immune-driven viral polymorphisms to compromise antiretroviral-based preexposure prophylaxis for prevention of HIV-1 infection
Author(s) -
Hiroyuki Gatanaga,
Zabrina L. Brumme,
Emily Adland,
Gustavo ReyesTerán,
Santiago ÁvilaRíos,
Carlos Mejía-Villatoro,
Tsunefusa Hayashida,
Takayuki Chikata,
Giang Van Tran,
Kinh Van Nguyen,
Rita I Meza,
Elsa Palou,
Humberto Valenzuela-Ponce,
Juan Miguel Pascale,
Guillermo Porras-Cortés,
Marvin Manzanero,
Guinevere Q. Lee,
Jeffrey N. Martin,
Mary Carrington,
Mina John,
S. Mallal,
Art F. Y. Poon,
Philip Goulder,
Masafumi Takiguchi,
Shinichi Oka
Publication year - 2017
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000001575
Subject(s) - human immunodeficiency virus (hiv) , medicine , pre exposure prophylaxis , virology , immunology , immune system , lentivirus , viral load , viral disease , men who have sex with men , syphilis
Long-acting rilpivirine is a candidate for preexposure prophylaxis (PrEP) for prevention of HIV-1 infection. However, rilpivirine resistance mutations at reverse transcriptase codon 138 (E138X) occur naturally in a minority of HIV-1-infected persons; in particular those expressing human leukocyte antigen (HLA)-B18 where reverse transcriptase-E138X arises as an immune escape mutation. We investigate the global prevalence, B18-linkage and replicative cost of reverse transcriptase-E138X and its regional implications for rilpivirine PrEP.